Predict your next investment

Holding Company
HEALTHCARE | Pharmaceuticals / Drugs
roche.com

See what CB Insights has to offer

Investments

8

Portfolio Exits

7

Partners & Customers

10

Service Providers

3

About Roche Holding

Roche Holding is the holding company of F. Hoffmann-La Roche (Roche), a Swiss multinational research-focused healthcare company that discovers, develops and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics.

Roche Holding Headquarter Location

Konzern-Hauptsitz Grenzacherstrasse 124

Basel, 4070,

Switzerland

+41-61-688 1111

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Roche Holding

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Roche Holding in 6 Expert Collections, including Digital Health.

D

Digital Health

404 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

C

Cancer

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

C

Conference Exhibitors

5,302 items

D

Diabetes

1,750 items

M

Medical Devices

4,399 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

H

Health Monitoring & Diagnostics

981 items

At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem

Roche Holding Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Roche Holding Rank

Latest Roche Holding News

02:30 ET Molecular Biology Enzymes, Kits, and Reagents Market to record USD 13.09 Bn growth | 39% of growth to originate from No...

Jan 26, 2022

| Technavio News provided by Share this article Share this article NEW YORK, Jan. 26, 2022 /PRNewswire/ -- The demand for molecular biology enzymes, kits, and reagents is increasing continuously among end-users. Hospitals, diagnostic centers, academic institutes, and research organizations extensively use molecular biology kits that include enzymes and reagents for disease diagnosis. Attractive Opportunities in Molecular Biology Enzymes, Kits, and Reagents Market by End-user and Geography - Forecast and Analysis 2021-2025 The advent of molecular technologies and the development of genomics have significantly increased the demand for molecular biology consumables at the genomic level. Also, the increasing use of molecular biology kits in the identification of disease-related genes and management of infectious diseases will positively influence market growth. Key Molecular Biology Enzymes, Kits, and Reagents Market Report Highlights: Market growth 2020-2025: USD 13.09 billion Growth momentum & CAGR: Accelerate at a CAGR of 14.61% YoY growth (%): 14.30% Key consumer countries: China, the US, Germany, the UK, and India Regional Market Analysis With 39% of the growth originating from North America, this region will record a faster growth rate during 2020-2025. The presence of a large number of players and increasing investments in the field of biotechnology are driving the growth of the molecular biology enzymes, kits, and reagents market in North America. The market growth in the region will be slower than the growth of the market in Asia. The US is the key market for molecular biology enzymes, kits, and reagents in North America. Key Vendors and Vendor Strategies Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Merck KGaA, New England Biolabs Inc., Promega Corp., QIAGEN NV, Rockland Immunochemicals Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc. are some of the dominant players in the molecular biology enzymes, kits, and reagents market. The molecular biology enzymes, kits, and reagents market is fragmented due to the presence of a large number of players. The vendors in the market are constantly adopting various organic and inorganic growth strategies to remain competitive in the market. Some vendors are focusing on forming strategic alliances or acquiring other players in the market to remain competitive. Agilent Technologies Inc.: The company offers polymerase chain reaction (PCR) enzymes and reagents, inhibitors, and kits for various applications such as reverse transcriptase cloning, cDNA from an RNA template, and high-fidelity cloning. F. Hoffmann-La Roche Ltd.: The company offers a range of molecular biology enzymes, kits, and reagents under its subsidiary Kapa Biosystems, Inc. Illumina Inc.: The company offers a range of common molecular biology reagents such as ribosomal RNA removal reagents, DNA/RNA extraction kits, PCR reagents, and others. Download our free sample report  to get a brief understanding of various vendors and their strategies. Key Market Drivers Our analysts have extensively outlined the information on the key market drivers and their impact on the molecular biology enzymes, kits, and reagents market. Increased use of proteins and reagents in biotechnology and pharmaceutical companies: Pharmaceutical companies are increasing the use of proteins and reagents in the development of drugs for rare genetic disorders and diseases. For example, pharma companies are using glucose oxidase enzymes to detect the amount of glucose in the blood as an indicator for the diagnosis of diabetes. The increasing use of proteins and reagents in many such applications is expected to drive the growth of the market during the forecast period. To know about a few other market drivers, trends, and challenges, Companies profiled Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Merck KGaA, New England Biolabs Inc., Promega Corp., QIAGEN NV, Rockland Immunochemicals Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc. Market Dynamics Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period. Customization purview If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact

Roche Holding Investments

8 Investments

Roche Holding has made 8 investments. Their latest investment was in Lead Pharma as part of their Project Finance on November 11, 2020.

CBI Logo

Roche Holding Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/17/2020

Project Finance

Lead Pharma

$11.86M

Yes

1

4/8/2020

Project Finance

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2019

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

10/28/2019

Biz Plan Competition

Subscribe to see more

Subscribe to see more

10

10/2/2018

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/17/2020

4/8/2020

12/19/2019

10/28/2019

10/2/2018

Round

Project Finance

Project Finance

Partnership

Biz Plan Competition

Partnership

Company

Lead Pharma

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$11.86M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Roche Holding Portfolio Exits

7 Portfolio Exits

Roche Holding has 7 portfolio exits. Their latest portfolio exit was Ariosa Diagnostics on August 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/16/2021

Acquired - II

2

5/18/2021

Acq - Fin

Subscribe to see more

Subscribe to see more

10

11/13/2020

Divestiture

Subscribe to see more

Subscribe to see more

10

10/15/2018

Divestiture

Subscribe to see more

Subscribe to see more

10

10/12/2018

Acquired - II

Subscribe to see more

Subscribe to see more

10

Date

8/16/2021

5/18/2021

11/13/2020

10/15/2018

10/12/2018

Exit

Acquired - II

Acq - Fin

Divestiture

Divestiture

Acquired - II

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Roche Holding Acquisitions

56 Acquisitions

Roche Holding acquired 56 companies. Their latest acquisition was TIB Molbiol on September 09, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/9/2021

$99M

Acquired

1

3/15/2021

$99M

Acq - Pending

26

10/7/2020

Series B

$99M

$52.2M

Acquired

1

9/21/2020

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/22/2020

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

9/9/2021

3/15/2021

10/7/2020

9/21/2020

5/22/2020

Investment Stage

Series B

Grant

Series C

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$52.2M

$99M

$99M

Note

Acquired

Acq - Pending

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

26

1

10

10

Roche Holding Partners & Customers

10 Partners and customers

Roche Holding has 10 strategic partners and customers. Roche Holding recently partnered with Glytec on January 1, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

1/12/2022

Vendor

Glytec

United States

Glytec and Roche Announce Strategic Partnership to Bring Digital Health Innovation in Glycemic Decision Support to the Hospital Bedside

Glytec , the only provider of cloud-based insulin management software across the continuum of care , today announced a strategic partnership with Roche , a division of the world 's largest biotech company and a global pioneer in pharmaceuticals and diagnostics .

3

10/18/2021

Partner

Ibex Medical Analytics

Israel

01:00 ET Roche announces collaboration with Ibex Medical Analytics to develop artificial intelligence-based digital pathology ap...

SANTA CLARA , Calif. , Oct. 18 , 2021 / PRNewswire / -- Roche today announced that it has entered an agreement with Ibex Medical Analytics , a global leader in artificial intelligence - based cancer diagnostics .

6

10/15/2021

Partner

PathAI

United States

Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

Basel , 15 October 2021 - Roche today announced that it has entered an agreement with PathAI , a global leader in artificial intelligence - powered technology for pathology .

4

10/15/2021

Supplier

PathAI

United States

Subscribe to see more

Subscribe to see more

10

10/14/2021

Partner

Prenosis

United States

Subscribe to see more

Subscribe to see more

10

Date

1/12/2022

10/18/2021

10/15/2021

10/15/2021

10/14/2021

Type

Vendor

Partner

Partner

Supplier

Partner

Business Partner

Glytec

Ibex Medical Analytics

PathAI

PathAI

Prenosis

Country

United States

Israel

United States

United States

United States

News Snippet

Glytec and Roche Announce Strategic Partnership to Bring Digital Health Innovation in Glycemic Decision Support to the Hospital Bedside

Glytec , the only provider of cloud-based insulin management software across the continuum of care , today announced a strategic partnership with Roche , a division of the world 's largest biotech company and a global pioneer in pharmaceuticals and diagnostics .

01:00 ET Roche announces collaboration with Ibex Medical Analytics to develop artificial intelligence-based digital pathology ap...

SANTA CLARA , Calif. , Oct. 18 , 2021 / PRNewswire / -- Roche today announced that it has entered an agreement with Ibex Medical Analytics , a global leader in artificial intelligence - based cancer diagnostics .

Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

Basel , 15 October 2021 - Roche today announced that it has entered an agreement with PathAI , a global leader in artificial intelligence - powered technology for pathology .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

6

4

10

10

Roche Holding Service Providers

3 Service Providers

Roche Holding has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - Pending

Commercial Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - Pending

Subscribe to see more

Subscribe to see more

Provider Type

Commercial Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Roche Holding Team

55 Team Members

Roche Holding has 55 team members, including current Chief Executive Officer, President, German De La.

Name

Work History

Title

Status

German De La

Chief Executive Officer, President

Current

Severin Schwan

Chief Executive Officer

Current

Santanu Chattopadhyay

Chief Operating Officer

Current

Babette Güldenpfennig

Senior Vice President

Current

Lance Little

Managing Director

Current

Name

German De La

Severin Schwan

Santanu Chattopadhyay

Babette Güldenpfennig

Lance Little

Work History

Title

Chief Executive Officer, President

Chief Executive Officer

Chief Operating Officer

Senior Vice President

Managing Director

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.